• Huadong Medicine Co Ltd
Correspondence address: 866 Mogan Mountain Road, 866 Mogan Mountain Road, Hangzhou, China, 310011
Governing Law: Company Law Of The People’S Republic Of China
Legal Form: Limited Liability Company
Nature of Control:
• Ownership of shares – 75% or more
• Ownership of voting rights – 75% or more
• Right to appoint and remove directors
• Right to appoint and remove directors with control over the trustees of a trust
• Right to appoint and remove directors as a member of a firm

• Mr Kaijun Hu China
Correspondence address: 23 Floor, Tower B Of Grand Place, No 5 Huizhong Road, Chaoyang District, Beijing, China, 100101
Date of birth: September 1962
Nationality: Chinese
Country of residence: China
Nature of control:
• Ownership of voting rights – 75% or more as a member of a firm
• Right to appoint and remove directors as a member of a firm
• Has significant influence or control as a member of a firm

• SPOONER, Christopher Paul – CEO
Correspondence address: Whitfield Court, 30 -32 Whitfield Street, London, W1T 2RQ
Role: Director
Date of birth: June 1968
Nationality: British
Country of residence: England
Occupation: Ceo

• LIU, Chengwei – Company Director
Correspondence address: 23/Floor, Tower B Of Grand Place, No.5 Huizhong Road, Chaoyang District, Beijing, 100101, China
Role: Director
Date of birth: April 1973
Nationality: Chinese
Country of residence: China
Occupation: Company Director

• OLBY, Alan Musgrave
Correspondence address: Whitfield Court, 30 -32 Whitfield Street, London, W1T 2RQ
Role: Director
Date of birth: February 1971
Nationality: British
Country of residence: England
Occupation: Chartered Accountant

• DUAN, Shizheng
Correspondence address: A601, Grand Place, No.5 Huizhong Road, Chaoyang District, Beijing, 100101, China
Role: Director
Date of birth: January 1968
Nationality: Chinese
Country of residence: China
Occupation: Senior Manager

• CHEN, Bo
Correspondence address: No. 866, Moganshan Road, Gongshu District, Hangzhou Zhejiang, 310011, China
Role: Director
Date of birth: October 1972
Nationality: Chinese
Country of residence: China
Occupation: Manager

• BURRELL, Jayne Katherine
Correspondence address: Whitfield Court, 30 -32 Whitfield Street, London, W1T 2RQ
Role: Companys’ Secretary

The Team

The Group’s principal activities are the development and commercialisation of medical aesthetic products through the Group’s direct sales teams in major aesthetic markets and through marketing partners on an international basis.

Sinclair’s current aesthetic portfolio comprises four brands:
• Silhouette Soft / InstaLift
• Ellansé
• Perfectha
• Sculptra

The Group owns these assets globally with the exception of Sculptra, which is exclusively licenced under a long-term agreement for Western Europe from Galderma.

• Statement of Capital (Share Capital)
Class of Shares: ORDINARY
Currency: GBP
Number Allotted: 580157084
Aggregate nominal value: 5801570.84
ALL SHARES CARRY EQUAL VOTING RIGHTS AND RIGHTS TO DIVIDENDS OR RETURN OF CAPITAL.

• Statement of Capital (Total)
Currency: GBP
Total Number of shares: 580157084
Total Aggregate nominal value: 5801570.84
Total Aggregate amount unpaid: 0

• Full Details of Shareholders

Shareholding 1: 580157084 Ordinary shares held as at the date of this confirmation statement
Name: Huadong Medicine Aesthetics Investment (Hong Kong) Limited

Strategy

• The company’s’ brands are marketed directly (in the UK, Spain, France, Germany, Brazil, South Korea, and from 2018 in the USA and Mexico) and through an established network of distributors in the Middle East, Asia, Central and Eastern Europe and Latin America.
• On 2018, the company was acquired by Huadong Medicine Co Limited
• The launch of Perfectha@Lidocaine products range is expected to drive a new period of growth for the brand.
• The group continues its development of an extended range of Perfectha@formulations, expected to launch in 2020/2021.
• The Group is in the process of developing a formal charities policy.
• In 2019, the Board agreed to early termination of the long-term licence agreement for Sculptra.
• The results from continuing operations for 2019 show revenue of £50.6 million, a 33% increase from the £38.1 million achieved for 2018.
• Selling, marketing and distribution costs increased by 10% in 2019 due to having a direct presence in the US for a full year and increasing the size of the local team during the year.

Principal risks and uncertainties:

• Risk associated with the commercial success of products
• Interruption to product supply
• Product liability risk
• Competition and intellectual property risk
• Regulatory risk – Company’s legal costs for 2018 were £ 3,793
• Brexit
• Foreign exchange risk

Ambitions

• To provide scientifically advanced products, exceptional practice support, and ongoing skill development to select highly trained aesthetic physicians; delivering unmatched patient outcomes and creating enhanced practice value.
• The company targets clinical demand for effective, high quality, longer duration, natural-looking and minimally invasive treatments.

Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in the leading EU markets, Brazil, Mexico and South Korea and a network of international distributors. The company has now expanded its operations in Canada, the United States and Russia.

Customer Reviews on Google:

1. Joanna Kumpin, 2020
“I have been using their products like: Ellanse , Silhouette Soft- thread lift and Perfectha. These products are really amazing and high quality.
I think Ellanse is my new favourite filler by far!
Sinclare provides great support for professionals. You can join their Sinclare College where you can revise you knowledge or gain some new information.
Highly recommended and definitely worth trying!”

2. Anonymous Review, 2020
“A product called Sculptra was injected into my face in 2012; and the procedure was performed by an incomptent medical stud2nt at the Royal free London.
Subsequently I have endured perminent injury and disfigurement to the point that I need reconstructive skin – grafting under my left eye. This is just part of the story.
I approached Sinclair pharma for information regarding Sculptra which they produce and supply and they refuse to answear my calls and / emails and block my messages.
So much for professional.standards. This a corrupt gangster run company that disregards the safety of its product by refusing to acknowledge the harm that their product can cause.
SHADY DUBIOUS COMPANY THAT IS HARMING PEOPLE WITH DODGY PRODUCTS.”

• They provide additional services to support partner physicians in their practice. Promoting Sinclair products, driving leads to the practice, increasing brand awareness and offering support for other marketing activities including open days, events, and promotions.
• They offer their partners cutting edge digital platforms and data analysis services to enable their physician customers to better understand and communicate with their patients.

The average monthly number of persons (including directors) employed by the group and company during 2019, amounted to 275 (2018: 231).

The company operates a global, cross-functional employee engagement committee. Their focus is to identify and run engagement activities, share ideas on local issues, and where necessary roll out solutions globally across Sinclair affiliates. This is supported by an annual employee survey, which gives an opportunity to provide anonymous feedback on different aspects of working at Sinclair Pharma, and management are then able to implement an action plan based on the findings of the survey. Following feedback from the 2019 survey, the Group has worked during 2020 to provide an improved employee benefits package to their employees.

Employee Reviews on Glassdoor

13 January 2020

Current Employee – Anonymous Employee

Have been working at Sinclair Pharma part-time for less than a year

Pros

Good benefits, good working environment, opportunity to travel, autonomy

Cons

very few to report yet!

Employee Reviews on Indeed

1. “No upwards mobility

Assistant Accountant (France, Spain & Netherlands) (Former Employee) –  Chester – October 12, 2017

The company offers a good package which includes healthcare and travel insurance. However there is limited upward mobility and support from management.”

• The Group operates in a socially and environmentally responsible manner. Despite being in a relatively low-impact industry, the Group proactively seeks ways of reducing any adverse impact upon our surroundings through recycling schemes, making more efficient use of utilities and seeking ways to reduce waste.
• The Group’s new UK offices are designed with energy saving devices and our recycling scheme has significantly increased the amount of paper recycled.
• In order to reduce unnecessary air travel, video conferencing facilities are available to employees.
• Company provides customers monthly with consumer-friendly Sinclair Pharma Brand content for Instagram

During 2020, the company has partnered with Zuellig Pharma, TAMER Group KSA and Suneva Medical Inc.

Annual Report File

Locations

General enquiries UK

Address
1st Floor, Whitfield Court
30-32 Whitfield Street
London W1T 2RQ,
United Kingdom

Corporate Office (include also) UK & Ireland Operations

Address
1st Floor, Whitfield Court
30-32 Whitfield Street
London WIT-2RQ, United Kingdom

Chester Office – Global Technical Administration

Address
Sinclair Pharma Ltd
Eden House
Lakeside
Chester Business Park
Chester
CH4 9QT

International Operations & French Operations

Address
44-46 rue de la Bienfaisance
75008, Paris

Germany & Austria Operations

Address
Sinclair Pharma GmbH
Kurfursten-Anlage 3
69115 Heidelberg
Germany

Spain

Address
Av de Castilla nº 2
Parque Empresarial de San Fernando.
Ed Dublin planta 2
28830 San Fernando de Henares.
Madrid
Spain

Sinclair Pharma US

Address
1 Technology Drive,
Suite F211, Irvine, California, 92618

Sinclair Pharma Brazil

Address
Av. Queiroz Filho, 1.560 – Sala 18G – Vila Hamburguesa
CEP 05319-000 – SÃo Paulo – SP – Brasil

Social Media

Facebook

LinkedIn

YouTube

Awards

Sinclair Pharma is proud to have been short-listed among finalists in the Aesthetic Awards 2019, in three categories:
1. ELLANSÉ for Best Product
2. Blair Stevens as Sales Representative of the Year
3. Sinclair Pharma as the Best Subsidiary

Articles

Sinclair Pharma Continues Global Expansion with the Introduction of Silhouette InstaLift® in Canada

Competitors List (alphabetical order)
Criterion: Industry subcategory, Company Size and Product

Merz Pharma

Valeant Pharmaceuticals (Solta Medical)